Alkem Laboratories Ltd.

•

alkemlabs.comBSE: 539523NSE: ALKEM

Market Cap₹ 60,853 Cr.

Current Price

High / Low₹ 5,934 / 5,051

Stock P/E28.2

Book Value₹ 1,197

Price to Book4.60

Dividend Yield1.04 %

ROCE21.3 %

ROE18.3 %

Face Value₹ 2

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2016 • Pharma Business: 100.0%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Company has a healthy return on capital (ROCE) of 20.8%
Company has consistently been profitable over the last 5 years
Operating margins have improved to 13.3% from 10.2%
Strong cash generation - operating cash flow backs reported profits (CFO/PAT 0.91x)
Company has a consistent dividend-paying track record
Company comfortably covers its interest (18.9x coverage)

CONS

Promoter holding has decreased over last 2 years: -6.7pp
Total debt has risen sharply - up 52.8% year on year
Company has delivered a poor profit growth of 7.8% over past five years
Recurring exceptional / one-off items are inflating headline profit

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTY PHARMA NIFTYLARGEMIDCAP250 NIFTYMIDCAP150 NIFTY MIDCAP 100 NIFTY MIDCAP 150

S.No.	Name
1.	SUNPHARMA	1842.00	36.54	441957.50	0.87	2901.23	26.53	15299.88	10.98	19.11	28.81
2.	DIVISLAB	9326.00	84.64	247576.00	0.32	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4975.00	86.76	189233.01	0.76	566.00	3.28	4921.00	57.32	19.27	33.81
4.	ZYDUSLIFE	1119.50	24.74	111670.55	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
5.	CIPLA	1365.00	32.72	110272.68	0.95	785.55	-39.18	7119.28	4.13	16.00	16.73
6.	LAURUSLABS	1970.35	97.37	106460.42	0.10	362.07	123.94	2026.31	29.10	18.20	31.50
7.	DRREDDY	1161.00	30.07	96906.38	0.69	435.60	-69.10	8099.80	-5.21	13.75	10.63
8.	AUROPHARMA	1675.45	25.97	96401.69	0.24	1032.03	25.22	9150.35	17.44	12.76	20.54
9.	LUPIN	2096.00	17.34	95842.92	0.86	1416.98	16.01	8276.89	34.28	28.86	29.59
10.	MANKIND	2277.00	46.04	94050.37	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
11.	GLENMARK	2416.90	37.94	68210.88	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	ALKEM	5089.50	28.21	60852.61	1.04	520.98	-22.00	3740.15	10.95	21.28	20.47

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	2,968	3,440	3,324	2,936	3,032	3,415	3,374	3,144	3,371	4,001	3,737	3,603	3,740
	2,579	2,693	2,616	2,534	2,423	2,662	2,615	2,752	2,632	3,080	2,909	3,086	3,121
Operating Profit	389	747	708	402	609	753	759	391	739	921	828	517	619
OPM %	13.11%	21.71%	21.29%	13.69%	20.08%	22.05%	22.51%	12.45%	21.92%	23.01%	22.16%	14.36%	16.56%
	66	6	42	76	120	134	93	146	149	104	90	65	153
Interest	30	30	25	27	29	28	36	28	30	35	42	54	47
Depreciation	72	74	70	83	80	79	85	112	88	94	95	106	100
Profit before Tax	353	648	655	367	619	780	731	396	771	896	781	423	771
Tax %	18.43%	5.12%	7.73%	17.11%	11.16%	10.04%	12.35%	18.50%	13.32%	12.97%	16.34%	40.48%	32.47%
Net Profit	0	0	0	0	550	702	641	322	668	779	653	251	521
	23.98	51.90	49.76	24.55	45.60	57.60	52.34	25.57	55.56	63.99	53.19	19.77	43.49

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	5,688	6,392	7,357	8,344	8,865	10,634	11,599	12,668	12,965	14,712	15,081
	4,689	5,383	6,242	6,871	6,923	8,581	9,990	10,422	10,452	11,718	12,196
Operating Profit	999	1,009	1,115	1,473	1,942	2,053	1,609	2,245	2,512	2,994	2,885
OPM %	17.56%	15.78%	15.15%	17.66%	21.91%	19.30%	13.88%	17.73%	19.38%	20.35%	19.13%
	112	115	88	104	233	148	113	189	494	419	412
Interest	45	55	55	65	59	52	107	112	122	161	178
Depreciation	101	143	193	253	275	304	310	299	357	382	395
Profit before Tax	965	926	955	1,260	1,842	1,844	1,305	2,023	2,527	2,871	2,871
Tax %	6.22%	31.05%	18.96%	8.77%	12.18%	8.89%	22.84%	10.46%	12.31%	18.03%	23.18%
Net Profit	905	638	774	1,149	1,618	1,680	1,007	1,811	2,216	2,353	2,206
EPS	74.61	52.77	63.61	94.26	132.57	137.63	82.31	150.21	181.14	192.54	—
Dividend Payout %	20.10%	24.63%	25.15%	26.52%	22.63%	24.70%	60.74%	26.63%	24.84%	27.53%	—

COMPOUNDED SALES GROWTH

10 Years:: 12%
5 Years:: 11%
3 Years:: 8%

COMPOUNDED PROFIT GROWTH

10 Years:: 12%
5 Years:: 8%
3 Years:: 33%

STOCK PRICE CAGR

10 Years:: 12%
5 Years:: 6%
3 Years:: 12%
1 Year:: -6%

RETURN ON EQUITY

10 Years:: 18%
5 Years:: 18%
3 Years:: 19%
Last Year:: 18%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	24	24	24	24	24	24	24	24	24	24
Minority Interest	115	122	133	148	181	209	390	402	449	529
	4,443	4,839	5,414	6,135	7,352	8,613	9,021	10,269	11,925	13,761
	671	1,012	957	1,711	1,742	2,654	1,552	1,739	1,687	2,380
Trade Payables	741	961	962	954	1,069	1,173	1,165	1,748	1,937	2,244
	-123	53	10	41	43	85	302	-122	-69	116
Total Liabilities	5,872	7,010	7,501	9,013	10,411	12,760	12,454	14,060	15,953	19,054
	1,797	2,284	2,530	2,908	2,793	2,902	2,683	2,873	2,852	3,871
Capital Work in Progress	299	381	493	363	393	339	310	148	477	138
	553	444	324	261	333	371	622	484	1,846	1,869
	1,206	1,442	1,500	1,819	2,312	3,006	2,608	2,661	2,922	3,333
	12	10	14	15	17	16	24	2,253	2,466	2,979
Cash & Bank	399	577	662	1,092	1,990	2,579	2,617	1,579	1,563	1,733
	1,605	1,873	1,978	2,554	2,572	3,547	3,591	4,062	3,827	5,131
Total Assets	5,872	7,010	7,501	9,013	10,411	12,760	12,454	14,060	15,953	19,054

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	735	469	1,031	868	1,666	1,508	1,956	1,948	1,913	1,963
Cash from Investing	-286	-357	-316	-741	-999	-1,435	113	-1,008	-1,299	-1,667
Cash from Financing	-138	85	-379	79	-272	380	-1,761	-1,145	-811	-503
	47	-7	84	-77	-5	55	35	-205	-197	-208

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026

Shareholding Pattern

Numbers in percentages

	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	56.38	55.66	55.66	55.13	53.04	51.20	51.20	51.20	49.70
	8.69	9.02	10.15	9.40	9.11	9.47	9.97	10.15	10.41
	18.56	19.21	18.01	19.42	21.80	21.93	21.54	21.39	22.64
Government	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	16.36	16.10	16.18	16.05	16.05	17.40	17.30	17.25	17.25

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-08

Press Release

2026-09-08 - Alkem Laboratories Limited has informed the Exchange regarding a press release dated September 08, 2026, titled "Press Release Alkem Laboratories Limited launches Renocia Exo , India s first patented Ginsenoside Exosome-based hair growth serum".

2026-08-27

Shareholders meeting

2026-08-27 - Alkem Laboratories Limited has informed the Exchange about Intimation under Regulation 30 and 44(3) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 ( SEBI LODR Regulations ) - Outcome of the 52nd Annual General Meeting of the Company and Disclosure of voting results thereat.

2026-08-20

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-20 - Alkem Laboratories Limited has informed the Exchange about Q1 FY2027 - Earnings Conference Call Transcript

2026-08-17

Shareholders meeting

2026-08-17 - Alkem Laboratories Limited has informed the Exchange regarding Proceedings of the meeting of the equity shareholders of the Company and Scrutinizer s Report on e-voting (remote e-voting and e-voting at the Meeting)

2026-08-15

Copy of Newspaper Publication

2026-08-15 - Alkem Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-14

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-14 - Alkem Laboratories Limited has informed the Exchange about Link of Recording

2026-08-14

Trading Window

2026-08-14 - Alkem Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

2026-08-14

General Updates

2026-08-14 - Alkem Laboratories Limited has informed the Exchange about Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ( SEBI LODR Regulations ).

2026-08-14

Investor Presentation

2026-08-14 - Alkem Laboratories Limited has informed the Exchange about Investor Presentation

News

Recent coverage and analyst commentary for ALKEM

Loading news…

🤖

AI Stock Analyst

Alkem Laboratories Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account